Neumora Therapeutics, Inc. Common Stock (NMRA) EBITDA Yield: History & Chart

Neumora Therapeutics, Inc. Common Stock(NMRA)

Biotechnology · Watertown, MA

$0.48-0.04 (-7.84%)

Delayed quote: Oct 6, 2026, 12:30 PM EDT

About Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Watertown, MA

63 employees

www.neumoratx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Josh Pinto

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Neumora Therapeutics, Inc. Common Stock (NMRA)	$89.70M	N/A	N/A	N/A	N/A
PMV Pharmaceuticals, Inc. (PMVP)vs ›	$89.60M	N/A	N/A	N/A	N/A
Rallybio Corporation (RLYB)vs ›	$89.38M	N/A	N/A	N/A	N/A
electroCore, Inc. (ECOR)vs ›	$90.38M	N/A	N/A	N/A	N/A
ImmuCell Corporation (ICCC)vs ›	$90.47M	6.65%	6.57%	5.72%	4.64%
Equillium, Inc. (EQ)vs ›	$90.70M	N/A	N/A	N/A	N/A
CareCloud, Inc. (CCLD)vs ›	$86.90M	21.57%	23.06%	41.09%	38.38%
Biomea Fusion, Inc. (BMEA)vs ›	$93.63M	N/A	N/A	N/A	N/A
Atara Biotherapeutics, Inc. (ATRA)vs ›	$86.36M	N/A	17.90%	17.90%	17.90%
Park Dental Partners, Inc. Common Stock (PARK)vs ›	$94.27M	N/A	2.46%	2.46%	2.46%

NAME

MARKET CAP

EBITDA YIELD

TTM

Neumora Therapeutics, Inc. Common Stock (NMRA)

$89.70M

N/A

PMV Pharmaceuticals, Inc. (PMVP)vs ›

$89.60M

N/A

Rallybio Corporation (RLYB)vs ›

$89.38M

N/A

electroCore, Inc. (ECOR)vs ›

$90.38M

N/A

ImmuCell Corporation (ICCC)vs ›

$90.47M

6.65%

6.57%

5.72%

4.64%

Equillium, Inc. (EQ)vs ›

$90.70M

N/A

CareCloud, Inc. (CCLD)vs ›

$86.90M

21.57%

23.06%

41.09%

38.38%

Biomea Fusion, Inc. (BMEA)vs ›

$93.63M

N/A

Atara Biotherapeutics, Inc. (ATRA)vs ›

$86.36M

N/A

17.90%

Park Dental Partners, Inc. Common Stock (PARK)vs ›

$94.27M

N/A

2.46%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

NMRA EBITDA Yield Metrics

NMRA Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics